CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zeo Scientifix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zeo Scientifix Inc
3321 College Avenue, Suite 246
Phone: (305) 370-0482p:305 370-0482 DAVIE, FL  33328  United States Ticker: ZEOXZEOX

Business Summary
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Company’s product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
7/31/202410/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Interim Chief Executive Officer, Chief Financial Officer, Director Ian T.Bothwell 62 6/1/2024 11/4/2016
Independent Non-Executive Vice Chairman of the Board ChuckBretz 65 9/23/2022 9/23/2022
Chief Medical Officer, Director George C.Shapiro 62 2/7/2019 9/1/2018
3 additional Officers and Directors records available in full report.

Business Names
Business Name
BPSR
General Surgical Florida, Inc.
Livin Again Inc.
OCEL
OCELD
ZEOX

General Information
Number of Employees: 23 (As of 10/31/2023)
Outstanding Shares: 6,582,419 (As of 7/31/2024)
Shareholders: 6,000
Stock Exchange: OTC


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024